Roche presented detailed phase 3 results showing its oral selective estrogen receptor degrader (SERD), giredestrant, produced progression‑free survival gains in patients without ESR1 mutations and in the overall intent‑to‑treat population. The evERA/FLAURA2‑adjacent data released at ESMO tied giredestrant to substantially reduced risk of progression versus standard endocrine therapy in previously treated ER‑positive, HER2‑negative disease, with stronger effects in ESR1‑mutant subgroups. Separately, updated study results presented at the meeting highlighted median PFS improvements and subgroup analyses intended to sharpen Roche’s regulatory positioning. Company leaders framed the data as evidence the oral SERD can benefit a broader population than earlier-generation degraders. The presentations included efficacy metrics and safety profiles required for submissions to regulators and for payers’ comparative assessments. For clinicians and development teams, the results add a new comparator to future trial design and could intensify competition among oral SERDs and hormonal degraders. SERD refers to selective estrogen receptor degraders — small molecules that degrade ER protein and block estrogen signaling in hormone‑driven breast cancers.